版本:
中国

BRIEF-Bluebird Bio announces interim Phase 1 dose escalation data for anti-BCMA CAR T product candidate

Nov 30 Bluebird Bio Inc

* Bluebird Bio announces interim phase 1 dose escalation data for its anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma

* 100% of patients in second and third dose cohorts achieved an objective response Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐